Xenetic Biosciences, Inc. XBIO

Xenetic Biosciences announces all-stock merger with Santersus, leaving existing shareholders with 15% stake in the combined entity. All-stock merger with Santersus dilutes existing Xenetic shareholders to 15% ownership and redefines company structure.

Xenetic Biosciences acquires Santersus to expand its therapeutic platform. Acquisition expands therapeutic platform via major strategic move for micro cap firm.

Xenetic Biosciences and Santersus AG signed a definitive share exchange agreement to establish a global leader in NET-targeting therapeutics. The share exchange creates a new global leader in NET-targeting therapeutics and represents a major strategic move for Xenetic Biosciences.

Xenetic Biosciences reported second quarter 2026 financial results and highlighted strengthened scientific foundation for continued advancement of its proprietary DNase platform. Routine quarterly financial reporting paired with incremental DNase platform updates signals moderate ongoing research progress without major strategic shifts.

Xenetic Biosciences presented ASCO 2026 data showing DNase I significantly improves CAR-T cell persistence, tumor control, and survival. Positive ASCO data on DNase I boosting CAR-T outcomes signals major potential for oncology pipeline progress and investor interest.

Xenetic Biosciences (XBIO) reported first quarter 2026 financial results and highlighted continued advancement of its DNase Oncology Platform. Q1 financial results and DNase oncology platform progress moderately influence financial performance and pipeline development without major shifts.

Xenetic Biosciences, Inc. announces abstract acceptance for presentation at the 2026 ASCO Annual Meeting. Abstract acceptance at ASCO signals clinical progress in oncology pipeline with potential to enhance market sentiment and visibility.

Xenetic Biosciences, Inc. presented positive preclinical data at the SITC Spring Scientific 2025 Cell Therapy Meeting, highlighting the potential of DNase I as an adjunctive treatment to enhance CAR T cell therapy in metastatic melanoma. The study showed that DNase I improved T cell infiltration and functionality by degrading neutrophil extracellular traps (NETs), leading to reduced tumor burden and prolonged survival in a murine model. The company aims to advance its DNase technology towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors. The findings indicate a significant enhancement in cancer treatment strategies, potentially altering the company's trajectory and investor sentiment.

Xenetic Biosciences, Inc. (XBIO) reported full year 2025 financial results. Full year financial results affect key financial performance and investor sentiment.

Xenetic Biosciences (XBIO) released Q4 earnings snapshot highlighting financial results for the quarter. Q4 earnings snapshots influence financial performance and investor sentiment but are balanced by biotech pipeline developments.

Xenetic Biosciences, Inc. has extended its research and development collaboration with an investigator at Scripps Research to further advance its DNase platform. This collaboration aims to enhance the development of DNase-based therapies, which could lead to significant advancements in treatment options. The collaboration is expected to significantly impact product innovation and the company's strategic direction.

Xenetic Biosciences, Inc. reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue, expenses, and net income. The company continues to focus on its innovative drug development pipeline and strategic partnerships, aiming to enhance its market position. Management provided insights into future growth prospects and ongoing projects, emphasizing their commitment to advancing biotechnology solutions. Financial results and strategic insights indicate a moderately noticeable influence on the company's future performance.

Xenetic Biosciences, Inc. (XBIO) reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its proprietary drug delivery technologies and partnerships aimed at advancing its pipeline. Despite challenges in the market, Xenetic remains committed to its strategic goals and innovation in biopharmaceuticals. The earnings report indicates moderate financial performance and ongoing strategic initiatives that could influence the company's future.

Xenetic Biosciences, Inc. has announced the pricing of an underwritten offering of common stock amounting to $4.5 million. The offering is expected to close on or about October 30, 2023, subject to customary closing conditions. The company intends to use the net proceeds for general corporate purposes, which may include funding research and development activities and working capital. The offering may provide necessary funding for research and development, impacting financial performance moderately.

Xenetic Biosciences, Inc. reported its financial results for the second quarter of 2025, highlighting key metrics such as revenue, net loss, and cash reserves. The company continues to focus on its proprietary drug development programs and strategic partnerships to enhance its market position. Management expressed optimism about upcoming milestones and ongoing projects aimed at advancing their therapeutic pipeline. The financial results indicate moderate performance, which may influence investor sentiment and operational aspects but are not expected to significantly alter the company's trajectory.

Xenetic Biosciences, Inc. (XBIO) reported a loss for Q2, falling short of revenue estimates. The company's financial performance has raised concerns among investors, as it continues to struggle with its revenue generation. Analysts are closely monitoring the situation to assess the potential implications for future growth and market positioning. The missed revenue estimates indicate challenges that may affect financial performance and investor sentiment.

Xenetic Biosciences, Inc. reported its Q2 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its proprietary drug delivery technologies and partnerships aimed at advancing its pipeline. Despite challenges in the market, Xenetic remains committed to its strategic goals and innovation in biopharmaceuticals. The earnings report indicates moderate financial performance and ongoing strategic initiatives that may influence the company's competitive positioning.

Xenetic Biosciences, Inc. has announced that a collaboration partner has entered into a clinical study agreement to further develop its DNase platform aimed at treating large B cell lymphoma. This agreement marks a significant step in advancing the therapeutic potential of the DNase technology in oncology. The clinical study agreement represents a major strategic move that could significantly impact the company's future performance and investor sentiment.

Xenetic Biosciences, Inc. has expanded its research and development collaboration with The Scripps Research Institute to enhance its DNase platform. This collaboration aims to advance the development of innovative therapeutics, leveraging Scripps' expertise in drug discovery and development. The partnership is expected to accelerate the progress of Xenetic's proprietary technologies and improve its product pipeline. The collaboration with a prestigious research institute is likely to significantly enhance Xenetic's product development and competitive positioning.

Xenetic Biosciences, Inc. announced that the first patient has been dosed in an exploratory clinical study evaluating DNase I in combination with FOLFIRINOX for treating unresectable, locally advanced, or metastatic pancreatic cancer. This collaboration aims to assess the safety and efficacy of the treatment regimen in this challenging cancer type. The initiation of this clinical study represents a significant strategic move that could enhance the company's position in the oncology market.

Xenetic Biosciences, Inc. reported its financial results for Q1 2025, highlighting a net loss of approximately $0.9 million and a revenue increase of 16.1% to $0.6 million. The company is focusing on exploratory clinical studies with partners, particularly advancing its DNase I development program for pancreatic carcinoma. Xenetic ended the quarter with $5.2 million in cash and announced a Clinical Study Agreement with PeriNess Ltd. to develop its DNase platform for treating osteosarcoma and Ewing sarcoma. The company aims to leverage strategic collaborations to enhance its technology and expand preclinical data supporting DNase I's use in various cancer treatments. The collaboration with PeriNess and the advancement of the DNase I program are significant strategic moves that could enhance the company's market position and investor sentiment.

Xenetic Biosciences, Inc. has released a virtual investor segment titled 'What This Means,' aimed at providing insights into the company's strategic direction and recent developments. This initiative is part of their efforts to enhance communication with investors and clarify the implications of their ongoing projects and research. The release of the virtual investor segment may moderately influence investor sentiment and understanding of the company's strategic direction.

Xenetic Biosciences, Inc. announced a Clinical Study Agreement with PeriNess Ltd. for an exploratory clinical study of its DNase I candidate, XBIO-015, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma. The study, led by Prof. Ronit Elhasid at the Tel-Aviv Sourasky Medical Center, aims to evaluate safety, tolerability, and efficacy of XBIO-015 in combination with chemotherapy. The research highlights the role of neutrophil extracellular traps (NETs) in poor prognosis for these cancers, and Xenetic's DNase I is designed to target these traps. The company is committed to advancing its DNase program and expanding clinical data through various oncology studies. The collaboration and clinical study represent a significant strategic move that could enhance product development and market positioning.

Xenetic Biosciences, Inc. (XBIO) reported its full-year 2024 earnings, revealing revenues that exceeded expectations. However, the earnings per share (EPS) fell short of forecasts, indicating mixed financial performance for the company. Revenues exceeding expectations may positively influence market sentiment, but the EPS shortfall suggests limited overall impact on the company's trajectory.

Xenetic Biosciences, Inc. reported its financial results for the year ended December 31, 2024, highlighting progress in its DNase-based technology aimed at treating difficult cancers. The company has extended collaborations with the University of Virginia and Scripps Research, and entered a Clinical Trial Services Agreement with PeriNess Ltd. to explore DNase I in combination with chemotherapy and immunotherapy for various cancers. The net loss for 2024 was approximately $4.0 million, with research and development expenses decreasing slightly. The company ended the year with about $6.2 million in cash and is focused on advancing its DNase program towards clinical trials. Significant advancements in clinical collaborations and technology development could alter the company's trajectory and investor sentiment.

Xenetic Biosciences, Inc. announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting, scheduled for March 12-14, 2025, in San Diego, CA. The presentation, titled 'DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma,' will be delivered by Alexey Stepanov, PhD. The company focuses on immuno-oncology technologies and is advancing its DNase platform to improve cancer treatment outcomes, particularly for pancreatic carcinoma and metastatic solid tumors. The acceptance of the abstract for presentation indicates significant progress in Xenetic's research and potential advancements in cancer treatment.

Xenetic Biosciences, Inc. extends Research Agreement with the University of Virginia for its DNase-Based oncology platform. The extension of the Research Agreement with a prestigious university indicates a significant strategic move that could impact the company's future product development and competitive positioning.

Xenetic Biosciences, Inc. extends research agreement with the University of Virginia to advance DNase-based oncology platform through 2025. Extension of research agreement with UVA to advance DNase-based oncology platform towards clinical proof-of-concept studies in multiple indications signifies a significant impact on Xenetic Biosciences' future and market performance.

Xenetic Biosciences, Inc. partners with PeriNess Ltd. to advance DNase I oncology program for pancreatic carcinoma and colorectal cancer. The collaboration with PeriNess is expected to significantly impact Xenetic Biosciences' future by accelerating the development of their systemic DNase I candidate for multiple indications.

Xenetic Biosciences, Inc. announced positive preclinical data on DNase I improving efficacy of anti-CTLA-4 immune checkpoint blockade in colorectal carcinoma. The positive preclinical data presented at the SITC meeting could significantly impact Xenetic Biosciences' future clinical development and market positioning.